Business
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 /Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported ...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year ended August 31, 2025 ("FY2025") and provided an update on operational progress achieved since the Company's leadership transition and Board renewal beginning in late 2024.","length":500,"tagName":"p"},{"type":"text","content":"Dr. Frederick D. Sancilio, Chairman and CEO of Lobe Sciences, stated: "During fiscal 2025, our focus was on strengthening the Company's financial position, reducing legacy liabilities, and ensuring that our core assets were funded in a manner that preserved long-term shareholder participation. By advancing L-130 (psilocin mucate) through Cynaptec Pharmaceuticals, Inc. and completing financing at the subsidiary level, we were able to secure capital for development while minimizing dilution at Lobe. We believe this approach better reflects the underlying value of the asset and provides a clearer path to advancing our programs without significant dilution of the Lobe shareholders."","length":701,"tagName":"p"},{"type":"text","content":"FY2025 Financial Highlights","length":27,"tagName":"p"},{"type":"text","content":"Lobe made significant progress strengthening its balance sheet and improving liquidity during FY2025:","length":101,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash increased to $5,854,118 on August 31, 2025, compared to $237,772 on August 31, 2024","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Short-term investments of $1,686,688 were held on August 31, 2025 (none reported on August 31, 2024)","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Working capital improved to a surplus of $5,163,526, compared to a deficit of $2,008,849 on August 31, 2024","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Convertible notes (current portion) decreased to $nil on August 31, 2025, from $641,374 on August 31, 2024","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Derivative liability decreased to $205,105 on August 31, 2025, from $603,724 on August 31, 2024","length":95,"tagName":"p"...